Merck Earnings Deep Dive: Oncology Engine Roars and Growth Pivot Accelerates, So Why the ‘Conservative’ 2026 Guidance?

While the core oncology asset KEYTRUDA remains robust and new launches like WINREVAIR and CAPVAXIVE are showing strong uptake momentum, shares dipped over 2% in pre-market trading. Market anxiety is primarily focused on the 2026 profit guidance, which appears conservative due to the looming impact of patent expirations and one-time M&A costs.

– Q4 Global Sales: $16.4 billion (+5% YoY), slightly beating the consensus estimate of $16.21 billion.

– Non-GAAP EPS: $2.04 (+19% YoY), topping expectations of $2.02.

– Full-Year Sales: Totaled $65 billion. KEYTRUDA sales reached $31.68 billion (+7% YoY), maintaining its status as the massive "cash cow."

– 2026 Revenue Guidance: $65.5–$67.0 billion, coming in below the consensus of $67.6 billion.

– 2026 Non-GAAP EPS Guidance: $5.00–$5.15, significantly below market expectations. Management explicitly noted this includes a roughly $3.65/share impact from one-time charges related to the Cidara Therapeutics acquisition.

1. GAAP Profits Hit by Short-Term Factors:

Q4 GAAP gross margin fell sharply to 66.2% from 75.5% a year prior. This was largely driven by restructuring costs (accelerated depreciation), inventory write-downs, amortization of intangibles, and the inventory fair value step-up from the Verona acquisition. These one-time or non-operating items significantly amplified cost pressures.

2. Non-GAAP Reflects Operational Resilience:

Stripping out those items, Q4 Non-GAAP gross margin remained strong at 79.7% (down only 110 basis points YoY), demonstrating that the profitability and pricing power of the core portfolio remain intact.

3. R&D Engine is Accelerating, Not Slowing:

While reported R&D expenses fell 15% YoY (due to large business development charges in the prior-year period), the R&D engine is actually speeding up. With approximately 80 Phase III studies currently underway and 18 positive Phase III readouts announced in 2025, the clinical pipeline is advancing aggressively.

– KEYTRUDA: Q4 sales of $8.37 billion (+7% YoY). Growth is shifting from late-stage treatment to earlier-stage indications (e.g., TNBC, NSCLC), effectively extending the product's lifecycle.

– WELIREG & Secondary Assets: WELIREG Q4 sales surged 37% to $220 million, proving Merck can cultivate a "second growth curve" within oncology.

– The Verdict: The key isn't just Keytruda’s growth, but leveraging its standard-of-care status to drive combos and new mechanisms that secure longer-term cash flow.

– GARDASIL (HPV): Q4 sales dropped 34% to $1.03 billion, acting as the primary drag on earnings. This was driven by weak demand in China and the completion of catch-up programs in Japan.

– CAPVAXIVE (Pneumococcal): Explosive growth to $279 million in Q4 (vs. $50 million YoY), showing a clear ramp-up trajectory.

– The Verdict: Short-term sentiment depends on when Gardasil stabilizes in China, while the mid-term pivot relies on Capvaxive successfully taking the baton.

– WINREVAIR: Q4 sales skyrocketed 133% to $467 million. It is in a rapid ramp-up phase, despite net pricing impacts from U.S. reimbursement policies.

– OHTUVAYRE: Acquired via Verona, this contributed $178 million in Q4 (vs. $36 million prior year), positioning it as a growing contributor in the respiratory space.

– The Verdict: These successes are direct evidence of Merck diversifying away from single-product dependency, creating a visible "second curve" on the balance sheet.

Facing slowing growth in its core pillars and a looming patent cliff, Merck is pitching a new "$70 Billion Growth Story."

KEYTRUDA’s growth has decelerated (from 18% in 2024 to 7%), and its core patent expires in 2028. Analysts predict biosimilars could erode $18 billion in sales within five years of expiration. Given Keytruda represents nearly half of total revenue, this concentration risk is critical.

Merck’s Counter-Strategy:

The company demonstrated its ability to execute, with revenue from new launches exploding from $70 million in Q2 2024 to $824 million in Q3 2025. At the JPM2026 conference, Merck outlined a roadmap to generate over $70 billion in commercial opportunities by the mid-2030s—double Keytruda’s expected 2028 sales.

Execution Path:

1. Focus: Resources concentrated on 10 key projects (including Sac-TMT ADC, oral PCSK9 inhibitor Enlicitide, and Ohtuvayre) responsible for 70% of that target.

2. Validation: The next 24 months are the "decisive window." Merck plans to de-risk $35 billion of this opportunity via intensive Phase III data readouts by end-of-2026.

3. Layered Defense: Using ADCs as near-term stabilizers, building autoimmune/respiratory pillars for the mid-term, and incubating cell/gene therapy for the long term.

Merck’s latest report sends a clear signal: ignore the short-term profit "noise" caused by one-time M&A costs and restructuring. The real story is the successful transition of the business model—funding a "second curve" of new blockbusters via the massive cash flows from Oncology.

While the stock may suffer volatility due to the conservative 2026 guidance, the medium-term investment thesis hinges on three validation points:

1. GARDASIL Stabilization: When will the bleed in China stop?

2. New Product Velocity: Can WINREVAIR, CAPVAXIVE, and OHTUVAYRE continue their beat-and-raise trajectory to drive quality revenue growth in 2026-2027?

3. Pipeline Succession: Can the next generation of oncology assets (ADCs/Combos) successfully convince the market to re-rate Merck for the "Post-Keytruda Era"?